138 related articles for article (PubMed ID: 15165635)
1. Divalproex-ER pharmacokinetics in older children and adolescents.
Dutta S; Zhang Y; Conway JM; Sallee FR; Biton V; Reed MD; Kearns GL
Pediatr Neurol; 2004 May; 30(5):330-7. PubMed ID: 15165635
[TBL] [Abstract][Full Text] [Related]
2. Once-daily dosing is appropriate for extended-release divalproex over a wide dose range, but not for enteric-coated, delayed-release divalproex: evidence via computer simulations and implications for epilepsy therapy.
Reed RC; Dutta S; Liu W
Epilepsy Res; 2009 Dec; 87(2-3):260-7. PubMed ID: 19892524
[TBL] [Abstract][Full Text] [Related]
3. Every-12-hour administration of extended-release divalproex in patients with epilepsy: impact on plasma valproic acid concentrations.
Reed RC; Dutta S; Cavanaugh JH; Locke C; Granneman GR
Epilepsy Behav; 2006 Mar; 8(2):391-6. PubMed ID: 16473558
[TBL] [Abstract][Full Text] [Related]
4. Bioequivalence of a new sustained-release formulation of sodium valproate, valproate modified-release granules, compared with existing sustained-release formulations after once- or twice-daily administration.
Dulac O; Alvarez JC
Pharmacotherapy; 2005 Jan; 25(1):35-41. PubMed ID: 15767218
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the bioavailability of 250 and 500 mg divalproex sodium extended-release tablets in healthy volunteers.
Dutta S; Zhang Y; Lee LL; O'Dea R
Biopharm Drug Dispos; 2004 Nov; 25(8):353-7. PubMed ID: 15378556
[TBL] [Abstract][Full Text] [Related]
6. Bioavailability of divalproex extended-release formulation relative to the divalproex delayed-release formulation.
Dutta S; Zhang Y
Biopharm Drug Dispos; 2004 Nov; 25(8):345-52. PubMed ID: 15378557
[TBL] [Abstract][Full Text] [Related]
7. Comparative absorption profiles of divalproex sodium delayed-release versus extended-release tablets -- clinical implications.
Dutta S; Reed RC; O'Dea RF
Ann Pharmacother; 2006 Apr; 40(4):619-25. PubMed ID: 16569797
[TBL] [Abstract][Full Text] [Related]
8. Does it really matter when a blood sample for valproic acid concentration is taken following once-daily administration of divalproex-ER?
Reed RC; Dutta S
Ther Drug Monit; 2006 Jun; 28(3):413-8. PubMed ID: 16778728
[TBL] [Abstract][Full Text] [Related]
9. Extended-release divalproex in child and adolescent outpatients with epilepsy.
Kernitsky L; O'Hara KA; Jiang P; Pellock JM
Epilepsia; 2005 Mar; 46(3):440-3. PubMed ID: 15730542
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of a guanfacine extended-release formulation in children and adolescents with attention-deficit-hyperactivity disorder.
Boellner SW; Pennick M; Fiske K; Lyne A; Shojaei A
Pharmacotherapy; 2007 Sep; 27(9):1253-62. PubMed ID: 17723079
[TBL] [Abstract][Full Text] [Related]
11. Effect of delayed and/or missed enteric-coated divalproex doses on valproic acid concentrations: simulation and dose replacement recommendations for the clinician.
Dutta S; Reed RC
J Clin Pharm Ther; 2006 Aug; 31(4):321-9. PubMed ID: 16882100
[TBL] [Abstract][Full Text] [Related]
12. A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults.
Swearingen D; Pennick M; Shojaei A; Lyne A; Fiske K
Clin Ther; 2007 Apr; 29(4):617-25. PubMed ID: 17617285
[TBL] [Abstract][Full Text] [Related]
13. Absolute bioavailability and absorption characteristics of divalproex sodium extended-release tablets in healthy volunteers.
Dutta S; Reed RC; Cavanaugh JH
J Clin Pharmacol; 2004 Jul; 44(7):737-42. PubMed ID: 15199078
[TBL] [Abstract][Full Text] [Related]
14. Successful initiation of combined therapy with valproate sodium injection and divalproex sodium extended-release tablets in the epilepsy monitoring unit.
Boggs JG; Preis K
Epilepsia; 2005 Jun; 46(6):949-51. PubMed ID: 15946337
[TBL] [Abstract][Full Text] [Related]
15. Clinical comparison of extended-release divalproex versus delayed-release divalproex: pooled data analyses from nine trials.
Smith MC; Centorrino F; Welge JA; Collins MA
Epilepsy Behav; 2004 Oct; 5(5):746-51. PubMed ID: 15380129
[TBL] [Abstract][Full Text] [Related]
16. Distinct absorption characteristics of oral formulations of valproic acid/divalproex available in the United States.
Dutta S; Reed RC
Epilepsy Res; 2007 Mar; 73(3):275-83. PubMed ID: 17208410
[TBL] [Abstract][Full Text] [Related]
17. Open-label steady-state pharmacokinetic drug interaction study on co-administered quetiapine fumarate and divalproex sodium in patients with schizophrenia, schizoaffective disorder, or bipolar disorder.
Winter HR; DeVane CL; Figueroa C; Ennis DJ; Hamer-Maansson JE; Davis PC; Smith MA
Hum Psychopharmacol; 2007 Oct; 22(7):469-76. PubMed ID: 17729385
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and safety of extended-release divalproex sodium tablets: morning versus evening administration.
Dutta S; Reed RC; Cavanaugh JH
Am J Health Syst Pharm; 2004 Nov; 61(21):2280-3. PubMed ID: 15552635
[TBL] [Abstract][Full Text] [Related]
19. Overnight versus progressive conversion of multiple daily-dose divalproex to once-daily divalproex extended release: which strategy is better tolerated by adults with intellectual disabilities?
Hellings JA; Barth FX; Logan M; Cook-Wiens G; Osorio I; Reed RC
J Clin Psychopharmacol; 2009 Oct; 29(5):492-5. PubMed ID: 19745651
[TBL] [Abstract][Full Text] [Related]
20. Functional half-life is a meaningful descriptor of steady-state pharmacokinetics of an extended-release formulation of a rapidly cleared drug : as shown by once-daily divalproex-ER.
Dutta S; Reed RC
Clin Drug Investig; 2006; 26(12):681-90. PubMed ID: 17274675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
